News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News TCT 2022 HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza Todd Neale September 16, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News EuroPCR 2014 Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure Caitlin E. Cox May 22, 2014